Scientific reports · 2021
Limited intestinal inflammation despite diarrhea, fecal viral RNA and SARS-CoV-2-specific IgA in patients with acute COVID-19.
СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Britton Graham J, Chen-Liaw Alice, Cossarini Francesca, Livanos Alexandra E, Spindler Matthew P, Plitt Tamar, Eggers Joseph, Mogno Ilaria, Gonzalez-Reiche Ana S, Siu Sophia, Tankelevich Michael, Grinspan Lauren Tal, Dixon Rebekah E, Jha Divya, van de Guchte Adriana, Khan Zenab, Martinez-Delgado Gustavo, Amanat Fatima, Hoagland Daisy A, tenOever Benjamin R, Dubinsky Marla C, Merad Miriam, van Bakel Harm, Krammer Florian, Bongers Gerold, Mehandru Saurabh, Faith Jeremiah J
Аннотация
Gastrointestinal symptoms are common in COVID-19 patients but the nature of the gut immune response to SARS-CoV-2 remains poorly characterized, partly due to the difficulty of obtaining biopsy specimens from infected individuals. In lieu of tissue samples, we measured cytokines, inflammatory markers, viral RNA, microbiome composition, and antibody responses in stool samples from a cohort of 44 hospitalized COVID-19 patients. SARS-CoV-2 RNA was detected in stool of 41% of patients and more frequently in patients with diarrhea. Patients who survived had lower fecal viral RNA than those who died. Strains isolated from stool and nasopharynx of an individual were the same. Compared to uninfected controls, COVID-19 patients had higher fecal levels of IL-8 and lower levels of fecal IL-10. Stool IL-23 was higher in patients with more severe COVID-19 disease, and we found evidence of intestinal virus-specific IgA responses associated with more severe disease. We provide evidence for an ongoing humeral immune response to SARS-CoV-2 in the gastrointestinal tract, but little evidence of overt inflammation.